23491-48-7

Usage

Chemical Properties

Solid

InChI:InChI=1/C11H16N4O2/c1-13-4-6-14(7-5-13)9-2-3-11(15(16)17)10(12)8-9/h2-3,8H,4-7,12H2,1H3/p+1

Upstream product

• 109-01-3 1-methyl-piperazine 
• 1635-61-6 5-chloro-2-nitroaniline 
• 68-12-2 N,N-dimethyl-formamide 
• 2369-11-1 5-fluoro-2-nitroaniline 
• 20289-35-4 5-iodo-2-nitro-aniline 

Downstream Products

• 54998-08-2 4-(4-methylpiperazino)-1,2-diaminobenzene 
• 402948-37-2 [6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]acetic acid ethyl ester 
• 77572-84-0 2-(4-aminophenyl)-5⁽⁶⁾-(4-methyl-1-piperazinyl)benzimidazole 
• 111861-08-6 5-(4-Methyl-piperazin-1-yl)-2-(4-nitro-phenyl)-1H-benzoimidazole 
• 23491-55-6 2'-(naphth-2-yl)-5-(4-methylpiperazinyl)-2,5'-bi-1H-benzimidazole 
• 23623-08-7 2'-phenyl-5-(4-methylpiperazinyl)-2,5'-bi-1H-benzimidazole 
• 23491-54-5 2'-m-tolyl-5-(4-methylpiperazinyl)-2,5'-bi-1H-benzimidazole 
• 23554-98-5 2'-(4-hydroxyphenyl)-5-(4-methyl-1-piperazinyl)-2,5'-bi-1H-benzimidazole 
• 81215-94-3 4-Amino-N-<2-amino-5-(4-methyl-1-piperazinyl)phenyl>-benzamide 
• 81215-97-6 2-(4-Isothiocyanatophenyl)-5⁽⁶⁾-(4-methyl-1-piperazinyl)-benzimidazole 
• 81215-96-5 2-(4-Aminophenyl)-5⁽⁶⁾-(4-methyl-1-piperazinyl)benzimidazole hydrochloride 
• 129244-58-2 2-(3,5-di-tert-butyl-4-hydroxybenzyl)-5⁽⁶⁾-(4-methyl-1-piperazinyl)benzimidazole 
• 129244-61-7 2-(3,5-di-tert-butyl-4-hydroxyphenethyl)-5⁽⁶⁾-(4-methyl-1-piperazinyl)benzimidazole 
• 129244-66-2 2-<2-(3,5-di-tert-butyl-4-hydroxyphenyl)-5'(6')-benzimidazolyl>-5(6)-<1-(4-methylpiperazinyl)>benzimidazole 

Relevant academic research and scientific papers

A new strategy for site-specific alkylation of DNA using oligonucleotides containing an abasic site and alkylating probes

Selective chemical reactions with DNA, such as its labelling, are very useful in many applications. In this paper, we discuss a new strategy for the selective alkylation of DNA using an oligonucleotide containing an abasic site and alkylating probes. We d

Benzimidazole compound, preparation method thereof and application of the benzimidazole compound in preparation of ferroptosis inhibitor

The invention discloses a benzimidazole compound, a preparation method thereof and application of the benzimidazole compound in preparation of a ferroptosis inhibitor. The benzimidazole compound has a structure as shown in a formula (I) or a formula (II)

Di-(benzimidazole)-1, 2, 3-triazole derivative as well as preparation and application thereof in inflammatory dermatosis

The invention belongs to the technical field of drug small molecules, and particularly discloses a brand-new di-(benzimidazole)-1, 2, 3-triazole derivative as well as preparation and application of the brand-new di-(benzimidazole)-1, 2, 3-triazole derivative. The research finds that the brand new compound has an excellent drug effect and low toxic and side effects on the aspect of inflammatory dermatosis, and has a good application prospect in the aspect of drug development of the inflammatory dermatosis.

Discovery of 5-(4-methylpiperazin-1-yl)-2-nitroaniline derivatives as a new class of SIRT6 inhibitors

SIRT6 is a deacetylase of histone H3 and inhibitors of SIRT6 have been thought as potential agents for treatment of diabetes. Herein we report the discovery of a series of new SIRT6 inhibitors containing the skeleton 1-phenylpiperazine. Among them, compound 5-(4-methylpiperazin-1-yl)-2-nitroaniline (6d) is the most potent one, which showed an IC50 value of 4.93 μM against SIRT6 in the Fluor de Lys (FDL) assay. It displayed KD values of 9.76 μM and 10 μM in surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) assays, respectively. In selectivity assay, 6d showed no activity against other members of the HDAC family (SIRT1-3 and HDAC1-11) at concentrations up to 200 μM. In a mouse model of type 2 diabetes, 6d could significantly increase the level of glucose transporter GLUT-1, thereby reducing blood glucose. Overall, this study provides a promising lead compound for subsequent drug discovery targeting SIRT6.

Pyrazole spleen tyrosine kinase inhibitor as well as preparation method and application thereof

The invention discloses a pyrazole spleen tyrosine kinase inhibitor, a preparation method thereof, a pharmaceutical composition containing the same, and application of the pyrazole spleen tyrosine kinase inhibitor and the pharmaceutical composition in the preparation of drugs for treating Syk-mediated diseases including cancers, inflammatory diseases and the like.

UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF

Provided are a urea compound represented by general formula (I), a pharmaceutically acceptable salt thereof, a preparation method therefor, and use thereof as an FLT3 tyrosine protein kinase inhibitor, particularly in the prevention and/or treating of cancer.

HPK1 inhibitor and application thereof

The invention belongs to the technical field of medicines, and specifically relates to an HPK1 inhibitor compound as shown in a formula (I) which is described in the specification or a pharmaceutically-acceptable salt and a stereoisomer of the HPK1 inhibi

Method for preparing dovitinib intermediate with microchannel reaction device

The invention discloses a method for preparing a dovitinib intermediate with a microchannel reaction device. The method comprises the following steps: (1) dissolving hydrochloric acid in ethanol to form a mixed solution, and enabling the mixed solution an

Discovery of 3-(5′-Substituted)-Benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors: Design, Synthesis, and Biological Evaluation

Fibroblast growth factor receptor (FGFR) represents an attractive oncology target for cancer therapy in view of its critical role in promoting cancer formation and progression, as well as causing resistance to approved therapies. In this article, we describe the identification of the potent pan-FGFR inhibitor (R)-21c (FGFR1-4 IC50 values of 0.9, 2.0, 2.0, and 6.1 nM, respectively). Compound (R)-21c exhibited excellent in vitro inhibitory activity against a panel of FGFR-amplified cell lines. Western blot analysis demonstrated that (R)-21c suppressed FGF/FGFR and downstream signaling pathways at nanomolar concentrations. Moreover, (R)-21c provided nearly complete inhibition of tumor growth (96.9% TGI) in NCI-H1581 (FGFR1-amplified) xenograft mice model at the dose of 10 mg/kg/qd via oral administration.

Synthesis and investigation of novel benzimidazole derivatives as antifungal agents

The rise and emergence of resistance to antifungal drugs by diverse pathogenic fungal strains have resulted in an increase in demand for new antifungal agents. Various heterocyclic scaffolds with different mechanisms of action against fungi have been investigated in the past. Herein, we report the synthesis and antifungal activities of 18 alkylated mono-, bis-, and trisbenzimidazole derivatives, their toxicities against mammalian cells, as well as their ability to induce reactive oxygen species (ROS) in yeast cells. Many of our bisbenzimidazole compounds exhibited moderate to excellent antifungal activities against all tested fungal strains, with MIC values ranging from 15.6 to 0.975?μg/mL. The fungal activity profiles of our bisbenzimidazoles were found to be dependent on alkyl chain length. Our most potent compounds were found to display equal or superior antifungal activity when compared to the currently used agents amphotericin B, fluconazole, itraconazole, posaconazole, and voriconazole against many of the strains tested.